Research advances in targeted therapy for gallbladder carcinoma

Liwen DU; Jiansheng LIU

doi:10.3969/j.issn.1001-5256.2023.12.032

Volume 39 Issue 12

Dec. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(12): 2965-2969

PDF( 562 KB)

Research advances in targeted therapy for gallbladder carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.12.032

Liwen DU¹,
Jiansheng LIU^{2
,
,
,}

1.
Shanxi Medical University，Taiyuan，030001，China
2.
Department of Hepatobiliary and Pancreatic Surgery，The First Hospital of Shanxi Medical University，Taiyuan 030001，China

More Information

Corresponding author: LIU Jiansheng， 147542533@qq.com （ORCID： 0000-0002-6038-2560）
Received Date: 2023-03-19
Accepted Date: 2023-05-12
Published Date: 2023-12-12

Abstract

Abstract

Gallbladder carcinoma （GBC） is a type of malignant tumor with an extremely poor prognosis， and at present， surgical operation is the most effective treatment method for this disease. Unfortunately， due to a lack of typical symptoms in the early stage， most patients have progressed to the advanced stage at the time of confirmed diagnosis and lost the opportunity for radical surgery. Among the currently available adjuvant treatments， targeted therapy has higher specificity and fewer side effects and has improved the prognosis of a variety of malignancies. With reference to the latest research advances in targeted therapy for GBC， this article reviews the current research status， potential targets， and targeted medications of targeted therapy for GBC， in order to provide a reference for the clinical treatment of GBC patients.
- Gallbladder Neoplasms,
- Signal Transduction,
- Therapeutics

FullText(HTML)

References(41)

References

[1]	MCNAMARA MG, LOPES A, WASAN H, et al. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer[J]. J Hepatol, 2020, 73( 5): 1109- 1117. DOI: 10.1016/j.jhep.2020.05.014.
[2]	HUNDAL R, SHAFFER EA. Gallbladder cancer: Epidemiology and outcome[J]. Clin Epidemiol, 2014, 6: 99- 109. DOI: 10.2147/CLEP.S37357.
[3]	LI YS, LI ML, LIU YB. Current status and future prospects of basic research on gallbladder carcinoma[J]. Chin J Pract Surg, 2021, 41( 1): 52- 55. DOI: 10.19538/j.cjps.issn1005-2208.2021.01.08. 李永盛, 李茂岚, 刘颖斌. 胆囊癌相关基础研究现状与展望[J]. 中国实用外科杂志, 2021, 41( 1): 52- 55. DOI: 10.19538/j.cjps.issn1005-2208.2021.01.08.
[4]	LIU YB, CHEN W. Current situation and prospect in the clinical treatment of gallbladder cancer[J]. Chin J Dig Surg, 2023, 22( 1): 81- 88. DOI: 10.3760/cma.j.cn115610-20230109-00013. 刘颖斌, 陈炜. 胆囊癌临床治疗的现状与展望[J]. 中华消化外科杂志, 2023, 22( 1): 81- 88. DOI: 10.3760/cma.j.cn115610-20230109-00013.
[5]	AZIZI AA, LAMARCA A, MCNAMARA MG, et al. Chemotherapy for advanced gallbladder cancer(GBC): A systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2021, 163: 103328. DOI: 10.1016/j.critrevonc.2021.103328.
[6]	LABRIE M, BRUGGE JS, MILLS GB, et al. Therapy resistance: Opportunities created by adaptive responses to targeted therapies in cancer[J]. Nat Rev Cancer, 2022, 22( 6): 323- 339. DOI: 10.1038/s41568-022-00454-5.
[7]	CARNEIRO BA, EL-DEIRY WS. Targeting apoptosis in cancer therapy[J]. Nat Rev Clin Oncol, 2020, 17( 7): 395- 417. DOI: 10.1038/s41571-020-0341-y.
[8]	ZHANG YJ, ZUO CM, LIU LG, et al. Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer[J]. J Hepatol, 2021, 75( 5): 1128- 1141. DOI: 10.1016/j.jhep.2021.06.023.
[9]	LI ML, ZHANG Z, LI XG, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway[J]. Nat Genet, 2014, 46( 8): 872- 876. DOI: 10.1038/ng.3030.
[10]	LI MW, HAN GH. Research advances in molecular targeted therapy for advanced biliary tract cancer[J]. J Clin Hepatol, 2014, 30( 11): 1212- 1216. DOI: 10.3969/j.issn.1001-5256.2014.11.032. 李明武, 韩国宏. 分子靶向药物治疗晚期胆道肿瘤的研究进展[J]. 临床肝胆病杂志, 2014, 30( 11): 1212- 1216. DOI: 10.3969/j.issn.1001-5256.2014.11.032.
[11]	TAN CS, KUMARAKULASINGHE NB, HUANG YQ, et al. Third generation EGFR TKIs: Current data and future directions[J]. Mol Cancer, 2018, 17( 1): 29. DOI: 10.1186/s12943-018-0778-0.
[12]	MODY K, STRAUSS E, LINCER R, et al. Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: A case report[J]. BMC Cancer, 2010, 10: 570. DOI: 10.1186/1471-2407-10-570.
[13]	LUBNER SJ, MAHONEY MR, KOLESAR JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: A phase II Consortium study[J]. J Clin Oncol, 2010, 28( 21): 3491- 3497. DOI: 10.1200/JCO.2010.28.4075.
[14]	CHEN JS, HSU C, CHIANG NJ, et al. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer[J]. Ann Oncol, 2015, 26( 5): 943- 949. DOI: 10.1093/annonc/mdv035.
[15]	CAI W, YUAN Y, GE WT, et al. EGFR target therapy combined with gemox for advanced biliary tract cancers: A meta-analysis based on RCTs[J]. J Cancer, 2018, 9( 8): 1476- 1485. DOI: 10.7150/jca.23290.
[16]	SONG XL, HU YP, LI YS, et al. Overview of current targeted therapy in gallbladder cancer[J]. Signal Transduct Target Ther, 2020, 5( 1): 230. DOI: 10.1038/s41392-020-00324-2.
[17]	YANG PZ, JAVLE M, PANG F, et al. Somatic genetic aberrations in gallbladder cancer: Comparison between Chinese and US patients[J]. Hepatobiliary Surg Nutr, 2019, 8( 6): 604- 614. DOI: 10.21037/hbsn.2019.04.11.
[18]	KIGUCHI K, CARBAJAL S, CHAN K, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma[J]. Cancer Res, 2001, 61( 19): 6971- 6976.
[19]	JEONG H, JEONG JH, KIM KP, et al. Feasibility of HER2-targeted therapy in advanced biliary tract cancer: A prospective pilot study of trastuzumab biosimilar in combination with gemcitabine plus cisplatin[J]. Cancers, 2021, 13( 2): 161. DOI: 10.3390/cancers13020161.
[20]	LEE CK, CHON HJ, CHEON J, et al. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: A multi-institutional phase 2 trial of the Korean Cancer Study Group(KCSG-HB19-14)[J]. Lancet Gastroenterol Hepatol, 2023, 8( 1): 56- 65. DOI: 10.1016/S2468-1253(22)00335-1.
[21]	YANG J, YAN J, LIU BR. Targeting VEGF/VEGFR to modulate antitumor immunity[J]. Front Immunol, 2018, 9: 978. DOI: 10.3389/fimmu.2018.00978.
[22]	ZHU AX, MEYERHARDT JA, BLASZKOWSKY LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: A phase 2 study[J]. Lancet Oncol, 2010, 11( 1): 48- 54. DOI: 10.1016/S1470-2045(09)70333-X.
[23]	IYER RV, GROMAN A, MA WW, et al. Gemcitabine(G), capecitabine(C) and bevacizumab(BV) in patients with advanced biliary cancers(ABC): Final results of a multicenter phase II study[J]. J Clin Oncol, 2015, 33( 15_suppl): 4078. DOI: 10.1200/jco.2015.33.15_suppl.4078.
[24]	XU JM, BAI YX, SUN HC, et al. A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer[J]. Cancer, 2021, 127( 21): 3975- 3984. DOI: 10.1002/cncr.33803.
[25]	BENGALA C, BERTOLINI F, MALAVASI N, et al. Sorafenib in patients with advanced biliary tract carcinoma: A phase II trial[J]. Br J Cancer, 2010, 102( 1): 68- 72. DOI: 10.1038/sj.bjc.6605458.
[26]	ALZAHRANI AS. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside[J]. Semin Cancer Biol, 2019, 59: 125- 132. DOI: 10.1016/j.semcancer.2019.07.009.
[27]	CORTI F, NICHETTI F, RAIMONDI A, et al. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives[J]. Cancer Treat Rev, 2019, 72: 45- 55. DOI: 10.1016/j.ctrv.2018.11.001.
[28]	TAN ES, CAO BW, KIM J, et al. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers[J]. Cancer, 2021, 127( 8): 1293- 1300. DOI: 10.1002/cncr.33364.
[29]	VALLE JW, LAMARCA A, GOYAL L, et al. New horizons for precision medicine in biliary tract cancers[J]. Cancer Discov, 2017, 7( 9): 943- 962. DOI: 10.1158/2159-8290.CD-17-0245.
[30]	COSTELLO BA, BORAD MJ, QI YW, et al. Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors[J]. Invest New Drugs, 2014, 32( 4): 710- 716. DOI: 10.1007/s10637-014-0096-3.
[31]	KIM RD, MCDONOUGH S, EL-KHOUEIRY AB, et al. Randomised phase II trial(SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer[J]. Eur J Cancer, 2020, 130: 219- 227. DOI: 10.1016/j.ejca.2020.01.026.
[32]	BEKAII-SAAB T, PHELPS MA, LI XB, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers[J]. J Clin Oncol, 2011, 29( 17): 2357- 2363. DOI: 10.1200/JCO.2010.33.9473.
[33]	DANG W, BIAN R, FAN QQ, et al. KIF11 promotes cell proliferation via ERBB2/PI3K/AKT signaling pathway in gallbladder cancer[J]. Int J Biol Sci, 2021, 17( 2): 514- 526. DOI: 10.7150/ijbs.54074.
[34]	YAN XZ, YANG PH, LIU H, et al. miR-4461 inhibits the progression of Gallbladder carcinoma via regulating EGFR/AKT signaling[J]. Cell Cycle, 2022, 21( 11): 1166- 1177. DOI: 10.1080/15384101.2022.2042775.
[35]	WEI Y, REN XX, GALBO PM Jr, et al. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target[J]. Sci Immunol, 2021, 6( 61): eabf9792. DOI: 10.1126/sciimmunol.abf9792.
[36]	LIU LG, LI Y, CAO DY, et al. SIRT3 inhibits gallbladder cancer by induction of AKT-dependent ferroptosis and blockade of epithelial-mesenchymal transition[J]. Cancer Lett, 2021, 510: 93- 104. DOI: 10.1016/j.canlet.2021.04.007.
[37]	LI ML, LIU FT, ZHANG F, et al. Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: A whole-exome sequencing analysis[J]. Gut, 2019, 68( 6): 1024- 1033. DOI: 10.1136/gutjnl-2018-316039.
[38]	NEYAZ A, HUSAIN N, KUMARI S, et al. Clinical relevance of PD-L1 expression in gallbladder cancer: A potential target for therapy[J]. Histopathology, 2018, 73( 4): 622- 633. DOI: 10.1111/his.13669.
[39]	PIHA-PAUL SA, OH DY, UENO M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies[J]. Int J Cancer, 2020, 147( 8): 2190- 2198. DOI: 10.1002/ijc.33013.
[40]	KANG J, JEONG JH, HWANG HS, et al. Efficacy and safety of pembrolizumab in patients with refractory advanced biliary tract cancer: Tumor proportion score as a potential biomarker for response[J]. Cancer Res Treat, 2020, 52( 2): 594- 603. DOI: 10.4143/crt.2019.493.
[41]	KIM RD, CHUNG V, ALESE OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020, 6( 6): 888- 894. DOI: 10.1001/jamaoncol.2020.0930.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (242) PDF downloads(51)

Research advances in targeted therapy for gallbladder carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.12.032

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research advances in targeted therapy for gallbladder carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.12.032

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content